Replimune Group, Inc. (REPL) Stock
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Ownership
About Replimune Group, Inc.
Replimune Group, Inc. is led by CEO Sushil Patel, employs 479 people, headquartered in US, publicly traded since 2018.
Replimune Group, Inc. (REPL) stock trades at $11.46 with a market capitalization of $1.08B. The stock is valued at a negative price-to-earnings (P/E) ratio of -4.15, reflecting a net loss over the last twelve months, price-to-book of 11.98, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.50 and $16.33, and currently trades 29.8% below its 52-week high.
On profitability, Replimune Group, Inc. generates a return on equity (ROE) of -159.32% (negative, reflecting a net loss), return on capital employed of -139.11%.
Replimune Group, Inc. by the numbers, 2017–2026
Between 2017 and 2026 Replimune Group, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-314.0M.
On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-297.0M.
Borrowings stand at $112.0M, cash from operations was $-280.0M in the latest year, positive in 0 of the last 10.
Return on equity has averaged -73.2% over five years, and was -189.2% in the most recent year.
The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.
Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.
Replimune Group, Inc. (REPL) — frequently asked questions
What is Replimune Group, Inc. (REPL) stock price today?
Replimune Group, Inc. (REPL) is currently trading at $11.46, down 4.42% today.
What is REPL P/E ratio?
Replimune Group, Inc.'s P/E ratio is -4.15. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.
What is REPL return on equity (ROE)?
Replimune Group, Inc.'s return on equity (ROE) is -159.32%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.
What is Replimune Group, Inc.'s market cap?
Replimune Group, Inc. has a market capitalization of $1.08B.
Does REPL pay a dividend?
Replimune Group, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does REPL carry?
Replimune Group, Inc. has a debt-to-equity ratio of 1.06. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is REPL's profit margin?
Replimune Group, Inc. reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.
What sector is REPL in?
Replimune Group, Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is REPL listed on?
Replimune Group, Inc. trades on NASDAQ under the ticker REPL.
What is REPL's 52-week range?
Over the last year Replimune Group, Inc. has traded between $1.50 and $16.33.
Related Healthcare Stocks
Popular Stocks
Screens REPL currently matches
On the figures above, Replimune Group, Inc. passes the filters for 4 of our ready-made screens, among them Small Cap Stocks, Stocks Under $100, Stocks Under $50. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.